Macular Disease Foundation Australia (MDFA) has announced the launch of its inaugural MDFA 25th Anniversary Award
The Therapeutic Goods Administration (TGA) approval of the new eye injection treatment SYFOVRE® (pegcetacoplan) is welcome news, as it will give many people with Geographic Atrophy a treatment option that they’ve never had before to slow the progression of the disease.
Welcome to our final Vision Voice newsletter for the year.
MDFA has received a positive response from the people participating in our new Eye Connect support service.
Macular Disease Foundation Australia (MDFA) has launched its new Research Impact Report, which showcases the groundbreaking projects our organisation has funded to help reduce the impact of macular disease.
The Federal Government has announced that from 1 July 2025, people receiving sight-saving eye (intravitreal) injections to treat macular disease will no longer receive health fund benefits for this treatment if it is performed in private hospitals and day surgeries.
The launch of the new Elisabeth Macdonald Memorial Award coincides with World Sight Day (9 October 2025) and marks the beginning of MDFA’s 25th anniversary year.
Dilini is one of MDFA’s Health Engagement Officers supporting people with diabetes-related eye conditions through our new Eye Connect service. A qualified Vision Scientist and training Optometrist, let’s find out more about Dilini and her experiences helping people with macular disease, Australia’s leading cause of blindness.
Affording sight-saving treatments and support is a challenge faced by many people in the macular disease community.